Conference Coverage
Late-onset MS is often more severe than earlier-onset MS
ST. LOUIS – Late-onset MS often has faster accrual of disability and might require different treatment options.
Conference Coverage
MS-related disability may be decreasing
STOCKHOLM – International data indicate that the prognosis of MS has improved, partly as a result of treatment.
News
FDA approves diroximel fumarate for relapsing MS
The oral drug, marketed as Vumerity, converts to the same active metabolite as dimethyl fumarate.
Conference Coverage
Adolescent lung inflammation may trigger later MS
STOCKHOLM – Swedish national health care registry studies show associations between pneumonia or infectious mononucleosis occurring in early...
Conference Coverage
Smoking impairs cognition and shrinks brain volume in MS
STOCKHOLM – New evidence suggests the damage may be partially reversible.
Conference Coverage
In patients with CIS, combined omics predicts conversion to clinically definite MS
STOCKHOLM – Oligoclonal band status is helpful for diagnosis, but cannot predict who will go on to develop clinically definite MS.
Conference Coverage
Investigators use ARMSS score to predict future MS-related disability
STOCKHOLM – The score is the basis for a measurement that is stable over time.
Conference Coverage
Intensive cognitive training may be needed for memory gains in MS
STOCKHOLM – Patients with MS saw the best results with the most intensive memory strategies.
Conference Coverage
Baseline neurofilament light levels track with brain volume loss in MS
STOCKHOLM – Ten-year data strengthen neurofilament light’s potential prognostic role.
Conference Coverage
Tocilizumab beat azathioprine for NMOSD
STOCKHOLM – The first-ever head-to-head trial compared the two drugs in highly relapsing neuromyelitis optica spectrum disorder.
Conference Coverage
Continuation of natalizumab treatment reduces risk of MS relapses during pregnancy
STOCKHOLM – Natalizumab treatment after the first trimester may not be associated with significant fetal risks.
Conference Coverage
Even with no disease activity, recurrence risk near 50% when stopping DMTs for MS
STOCKHOLM – Younger patients had a significantly higher risk of recurrence when stopping disease modifying therapy.
Conference Coverage
Plasma exchange in natalizumab-related PML shows no benefit, possible harm
STOCKHOLM – Biggest-ever study of natalizumab-associated PML in patients with multiple sclerosis raises red flag regarding common practice of...
Conference Coverage
Ofatumumab has superior efficacy in relapsing-remitting MS, compared with teriflunomide
STOCKHOLM – The monoclonal antibody reduced annualized relapse rate and the risk of confirmed disability worsening,...
Conference Coverage
Average daily step count reflects disability in MS
STOCKHOLM – Step count can be monitored remotely and correlates with measures of walking performance, cognitive...
Conference Coverage
In highly active MS, is skipping gadolinium an option?
STOCKHOLM – Though skipping contrast missed a small number of lesions, most patients would still have been classified and treated correctly.
Conference Coverage
Most patients with RIS develop MS within 10 years
STOCKHOLM – The conversion rate jumps to 87% in the presence of four risk factors at baseline.
Conference Coverage
Multimedia
Question 1 of 5